A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

被引：1

作者：

Richardson, Paul G. ^{[1
]}

Jagannath, Sundar ^{[2
]}

Moreau, Philippe ^{[3
]}

Jakubowiak, Andrzej ^{[4
]}

Raab, Marc S. ^{[5
,6
]}

Facon, Thierry ^{[7
]}

Vij, Ravi ^{[8
]}

White, Darrell J. ^{[9
]}

Reece, Donna ^{[10
]}

Benboubker, Lotfi ^{[11
]}

Zonder, Jeffrey A. ^{[12
]}

Deng, Wei ^{[13
]}

Kroog, Glenn ^{[14
]}

Singhal, Anil K. ^{[13
]}

Lonial, Sagar ^{[15
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mt Sinai Med Ctr, New York, NY 10029 USA

[3] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[5] Heidelberg Univ, Med Ctr, Heidelberg, Germany

[6] German Canc Res Ctr, Heidelberg, Germany

[7] Hop Claude Huriez, Serv Malad Sang, Lille, France

[8] Washington Univ, Sch Med, St Louis, MO USA

[9] Queen Elizabeth 2 Hlth Sci Ctr, Div Hematol, Halifax, NS, Canada

[10] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[11] Hop Bretonneau, Ctr Reg Cancerol Henry Kaplan CHRU Tours, Serv Hematol & Therapies Cellulaires, Tours, France

[12] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[13] Abbott Biotherapeut Corp, Redwood City, CA USA

[14] Bristol Myers Squibb Co, Princeton, NJ USA

[15] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

202

引用

页数：2

共 50 条

[41] Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN plus DEX) vs LEN plus DEX in relapsed/refractory multiple myeloma (R/R MM).
Alsaid, Nimer
McBride, Ali
Agarwal, Amit Balkrishna
Mutairi, Abdulaali
Anwer, Faiz
Abraham, Ivo
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[42] A PHASE II SINGLE-ARM SAFETY STUDY OF ELOTUZUMAB IN COMBINATION WITH THALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Mateos, M. V.
Granell, M.
Oriol Rocafiguera, A.
Martinez Lopez, J.
Blade, J.
Hernandez, M. T.
Martin Sanchez, J.
Gironella, M.
Lynch, M.
Bleickardt, E.
Paliwal, P.
Singhal, A.
San Miguel, J.
HAEMATOLOGICA, 2014, 99 : 361 - 362
[43] Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM)
Wang, M.
Bensinger, W.
Martin, T.
Alsina, M.
Siegel, D. S. D.
Gabrail, N. Y.
Hari, P.
Singhal, S.
Vescio, R. A.
Assouline, S. E.
Kunkel, L. A.
Vallone, M.
Wong, A.
Niesvizky, R.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[44] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Yee, Andrew J.
Laubach, Jacob P.
Campagnaro, Erica L.
Lipe, Brea C.
Nadeem, Omar
Friedman, Robb S.
Cole, Craig E.
O'Donnell, Elizabeth K.
Bianchi, Giada
Branagan, Andrew R.
Shapiro, Samantha J.
Harrington, Cynthia C.
Burke, Jill N.
Gammon, Marilyn T.
Lively, Kathleen J.
Thorburn, Cassandra A.
Mann, Mason L.
Lohr, Jens G.
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur S.
BLOOD, 2019, 134
[45] Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM)
Richardson, P. G.
Weber, D. M.
Mitsiades, C. S.
Dimopoulos, M. A.
Harousseau, J.
Howe, J.
Graef, T.
Byrne, C.
Anderson, K. C.
Siegel, D. S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[46] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Jian Hou
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Huisheng Ai
Jingshan Zhang
Honeylet Wortman-Vayn
Nianhang Chen
Jay Mei
Jianmin Wang
Journal of Hematology & Oncology, 6
[47] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Hou, Jian
Du, Xin
Jin, Jie
Cai, Zhen
Chen, Fangping
Zhou, Dao-bin
Yu, Li
Ke, Xiaoyan
Li, Xiao
Wu, Depei
Meng, Fanyi
Ai, Huisheng
Zhang, Jingshan
Wortman-Vayn, Honeylet
Chen, Nianhang
Mei, Jay
Wang, Jianmin
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
[48] Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma RRMM)
Kumar, Shaji
Grzasko, Norbert
Delimpasi, Sossana
Jedrzejczak, Wieslaw
Grosicki, Sebastian
Kyrtsonis, Marie Christine
Spencer, Andrew
Gupta, Neeraj
Teng, Zhaoyang
Byrne, Catriona
Labotka, Richard
Dimopoulos, Meletios Athanasios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01) : E131 - E131
[49] Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Kumar, Shaji
Grzasko, Norbert
Delimpasi, Sosana
Jedrzejczak, Wieslaw W.
Grosicki, Sebastian
Kyrtsonis, Marie-Christine
Spencer, Andrew
Gupta, Neeraj
Teng, Zhaoyang
Byrne, Catriona
Labotka, Richard
Dimopoulos, Meletios A.
BLOOD, 2016, 128 (22)
[50] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
Vij, Ravi
Richardson, Paul Gerard Guy
Jagannath, Sundar
Siegel, David Samuel DiCapua
Baz, Rachid C.
Srinivasan, Shankar
Larkins, Gail
Zaki, Mohamed H.
Hussein, Mohamad A.
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →